10 research outputs found

    Elesclomol restores mitochondrial function in genetic models of copper deficiency

    Get PDF
    © The Author(s), 2018. This article is distributed under the terms of the Creative Commons Attribution License. The definitive version was published in Proceedings of the National Academy of Sciences of the United States of America 115 (2018): 8161-8166, doi:10.1073/pnas.1806296115.Copper is an essential cofactor of cytochrome c oxidase (CcO), the terminal enzyme of the mitochondrial respiratory chain. Inherited loss-of-function mutations in several genes encoding proteins required for copper delivery to CcO result in diminished CcO activity and severe pathologic conditions in affected infants. Copper supplementation restores CcO function in patient cells with mutations in two of these genes, COA6 and SCO2, suggesting a potential therapeutic approach. However, direct copper supplementation has not been therapeutically effective in human patients, underscoring the need to identify highly efficient copper transporting pharmacological agents. By using a candidate-based approach, we identified an investigational anticancer drug, elesclomol (ES), that rescues respiratory defects of COA6-deficient yeast cells by increasing mitochondrial copper content and restoring CcO activity. ES also rescues respiratory defects in other yeast mutants of copper metabolism, suggesting a broader applicability. Low nanomolar concentrations of ES reinstate copper-containing subunits of CcO in a zebrafish model of copper deficiency and in a series of copper-deficient mammalian cells, including those derived from a patient with SCO2 mutations. These findings reveal that ES can restore intracellular copper homeostasis by mimicking the function of missing transporters and chaperones of copper, and may have potential in treating human disorders of copper metabolism.This work was supported by National Institutes of Health Awards R01GM111672 (to V.M.G.), R01 DK110195 (to B.-E.K.), and DK 44464 (to J.D.G.); Welch Foundation Grant A-1810 (to V.M.G.); and Canadian Institutes of Health Research Operating Grant MOP 133562 (to S.C.L.)

    Molecular Mechanisms of Copper Delivery to the Mitochondrial Cytochrome C Oxidase

    Get PDF
    Copper is required for the activity of cytochrome c oxidase (CcO), the mitochondrial enzyme that catalyzes cellular respiration. Copper delivery to CcO is a complex process requiring a number of proteins, and loss-of-function mutations in these proteins diminish CcO activity, causing rare mitochondrial disorders, for which no effective therapy currently exists. A lack of understanding of the basic mechanisms for copper transport to the mitochondria and ultimately to CcO has been the main bottleneck in developing therapeutic strategies for these disorders. To address this gap in our knowledge, I utilized a multi-disciplinary approach involving chemical biology, structural biology, and yeast genetics to identify small molecules and genes that facilitate copper transport to the mitochondrial CcO. First, using a chemical biology approach, I determined that elesclomol (ES), an investigational anticancer drug, is a potent copper delivery agent to mitochondria. I showed that ES supplementation rescues respiratory growth of several yeast copper metabolism mutants, including cells lacking Coa6, a CcO assembly factor. ES also restored CcO levels in a series of copper-deficient mammalian cells and in a zebrafish model of copper deficiency. These findings demonstrate the applicability of ES to more complex eukaryotic cells and intact multicellular organisms. Second, I utilized nuclear magnetic resonance (NMR) spectroscopy to uncover the structure and function of COA6, a new member of the CcO copper delivery pathway that was discovered in our laboratory. I collaborated with structural biologists to solve the solution structure of human COA6, which revealed a CHCH domain typically found in he redox-active proteins in the mitochondrial intermembrane space. Consistent with its redox role, I showed that COA6 function can be bypassed in the reducing environment. Interaction mapping and redox potential determination of COA6 and its client proteins showed that COA6 facilitates copper delivery to CcO by acting as a thiol-disulfide reductase. Finally, I utilized yeast genetics to uncover overlapping functions of COA6 and SCO2, a well-known member of the copper delivery pathway to CcO. Taken together, this dissertation describes molecular mechanisms of copper delivery to the mitochondrial CcO by both the interplay of CcO assembly factors and through pharmacological means

    Multiple metabolic requirements for size homeostasis and initiation of division in Saccharomyces cerevisiae

    No full text
    Most cells must grow before they can divide, but it is not known how cells determine when they have grown enough so they can commit to a new round of cell division. Several parameters affect the timing of initiation of division: cell size at birth, the size cells have to reach when they commit to division, and how fast they reach that size. We report that Saccharomyces cerevisiae mutants in metabolic and biosynthetic pathways differ in these variables, controlling the timing of initiation of cell division in various ways. Some mutants affect the size at birth, size at initiation of division, the rate of increase in size, or any combination of the above. Furthermore, we show that adenylate kinase, encoded by ADK1, is a significant determinant of the efficiency of size control mechanisms. Finally, our data argue strongly that the cell size at division is not necessarily a function of the rate cells increase in size in the G1 phase of the cell cycle. Taken together, these findings reveal an unexpected diversity in the G1 cell cycle phenotypes of metabolic and biosynthetic mutants, suggesting that growth requirements for cell division are multiple, distinct and imposed throughout the G1 phase of the cell cycle

    Noncanonical role of singleminded-2s in mitochondrial respiratory chain formation in breast cancer

    No full text
    Abstract Dysregulation of cellular metabolism is a hallmark of breast cancer progression and is associated with metastasis and therapeutic resistance. Here, we show that the breast tumor suppressor gene SIM2 promotes mitochondrial oxidative phosphorylation (OXPHOS) using breast cancer cell line models. Mechanistically, we found that SIM2s functions not as a transcription factor but localizes to mitochondria and directly interacts with the mitochondrial respiratory chain (MRC) to facilitate functional supercomplex (SC) formation. Loss of SIM2s expression disrupts SC formation through destabilization of MRC Complex III, leading to inhibition of electron transport, although Complex I (CI) activity is retained. A metabolomic analysis showed that knockout of SIM2s leads to a compensatory increase in ATP production through glycolysis and accelerated glutamine-driven TCA cycle production of NADH, creating a favorable environment for high cell proliferation. Our findings indicate that SIM2s is a novel stabilizing factor required for SC assembly, providing insight into the impact of the MRC on metabolic adaptation and breast cancer progression
    corecore